Snake oil, it turns out, motivated the founding of the FDA. The term “snake oil” arose out of a controversy from the late 1800s, when hucksters would sell elixirs claiming to be anti-inflammatory snake oil. Most of these products contained no snake oil and had no health benefits, sometimes even causing harm to consumers.

Scott Gottlieb and Luciana Borio, a former director for medical and biodefense preparedness policy at the National Security Council,

Thousands of Americans are diagnosed every year with Parkinson’s Disease. It’s a movement disorder that affects the central nervous system. Tremor is a common symptom. The Food and Drug Administration recently approved a new drug for those living with advanced Parkinson’s.

The FDA announced several recalls in December 2024, including Lay’s potato chips, cucumbers, puppy food, and dietary supplements, due to contamination, undeclared allergens, or safety concerns.

A discussion of the development of consumer protection law in the US through the enactment of key legislation and formation of the Food and Drug Administration (FDA).

Most of the recalls are contamination or allergen-based. While 2025 is near, there are still callbacks to be aware of. Here is a list of December recalls according to the FDA. FDA

The U.S. Food and Drug Administration redefined its parameters for “healthy” food for the first time in 30 years.

Dietary supplements — vitamins, minerals, botanicals and probiotics — are more popular than ever. Do they make a difference? Research is mixed.

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.

The FDA is urging anyone who has the cat food in question to return it to their place of purchase or destroy it.

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell lung cancer.